VectorY expands PIONEER-ALS phase 1/2 trial to 36 participants

VectorY said it expanded its global PIONEER-ALS phase 1/2 clinical trial of VTx-002 from 12 to 36 participants. The study is evaluating safety, tolerability, pharmacokinetics and pharmacodynamic effects in people with ALS.